73 related articles for article (PubMed ID: 12799254)
21. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
[TBL] [Abstract][Full Text] [Related]
22. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.
Rubenstein JL; Fridlyand J; Abrey L; Shen A; Karch J; Wang E; Issa S; Damon L; Prados M; McDermott M; O'Brien J; Haqq C; Shuman M
J Clin Oncol; 2007 Apr; 25(11):1350-6. PubMed ID: 17312328
[TBL] [Abstract][Full Text] [Related]
24. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
25. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
Pels H; Schmidt-Wolf IG; Glasmacher A; Schulz H; Engert A; Diehl V; Zellner A; Schackert G; Reichmann H; Kroschinsky F; Vogt-Schaden M; Egerer G; Bode U; Schaller C; Deckert M; Fimmers R; Helmstaedter C; Atasoy A; Klockgether T; Schlegel U
J Clin Oncol; 2003 Dec; 21(24):4489-95. PubMed ID: 14597744
[TBL] [Abstract][Full Text] [Related]
26. Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma.
Mason JO; Fischer DH
Ophthalmology; 2003 Jun; 110(6):1241-4. PubMed ID: 12799254
[TBL] [Abstract][Full Text] [Related]
27. Primary CNS lymphoma.
Gerstner E; Batchelor T
Expert Rev Anticancer Ther; 2007 May; 7(5):689-700. PubMed ID: 17492932
[TBL] [Abstract][Full Text] [Related]
28. Advances for the treatment of primary central nervous system lymphoma (review).
Yamanaka R; Tanaka R
Oncol Rep; 2004 Sep; 12(3):563-8. PubMed ID: 15289838
[TBL] [Abstract][Full Text] [Related]
29. Primary central nervous system lymphoma: recent progress, many remaining questions.
Swinnen LJ
Curr Opin Oncol; 2009 Sep; 21(5):393-6. PubMed ID: 19593137
[TBL] [Abstract][Full Text] [Related]
30. Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals.
Mazhar D; Stebbing J; Bower M
Expert Rev Anticancer Ther; 2006 Mar; 6(3):335-41. PubMed ID: 16503851
[TBL] [Abstract][Full Text] [Related]
31. Intraocular lymphoma: report of three cases and review of the literature.
Trudeau M; Shepherd FA; Blackstein ME; Gospodarowicz M; Fitzpatrick P; Moffatt KP
Am J Clin Oncol; 1988 Apr; 11(2):126-30. PubMed ID: 3282423
[TBL] [Abstract][Full Text] [Related]
32. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
33. Central nervous system-directed preventative therapy in adults with lymphoma.
McMillan A
Br J Haematol; 2005 Oct; 131(1):13-21. PubMed ID: 16173958
[TBL] [Abstract][Full Text] [Related]
34. Primary central nervous system lymphoma: curable without toxicity?
DeAngelis LM
Cancer J Sci Am; 1996; 2(3):137-9. PubMed ID: 9166513
[No Abstract] [Full Text] [Related]
35. Primary CNS lymphoma: a clinician's guide.
Schäfer N; Glas M; Herrlinger U
Expert Rev Neurother; 2012 Oct; 12(10):1197-206. PubMed ID: 23082736
[TBL] [Abstract][Full Text] [Related]
36. Excessive spinal cord toxicity from intensive central nervous system-directed therapies.
Watterson J; Toogood I; Nieder M; Morse M; Frierdich S; Lee Y; Moertel CL; Priest JR
Cancer; 1994 Dec; 74(11):3034-41. PubMed ID: 7954266
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]